New drug shows promise in treating psoriatic arthritis, ankylosing spondylitis & psoriasis
Rheumatology Drug Updates
Information on new approvals and medication safety that rheumatologists need to know
Glaxo’s Move on Physician Compensation Could Signal Shift in Pharmaceutical Promotions
GlaxoSmithKline has decided to stop paying physicians to promote its products and to cease tying sales-representative compensation to the number of prescriptions physicians write. (posted Feb. 14)
Rheumatology Drug Updates
Information on new approvals and medication safety that rheumatologists need to know
Pharmacy-based Arthritis Screening Debuts in Canada
Co-sponsored program between the Ministry of Health and pharmacy chain tasks pharmacists with screening people for knee osteoarthritis
Rheumatology Drug Updates
Information on new approvals and medication safety that rheumatologists need to know
2013 ACR/ARHP Annual Meeting: Researchers Explore Role of Pathogens, Quality of Care in Rheumatoid Arthritis
Funding by the Rheumatology Research Foundation has furthered studies on the impact of infectious agents and autoantigens, periodontal disease, and disease-modifying antirheumatic drugs on patients with RA
2013 ACR/ARHP Annual Meeting: Rheumatology Year in Review
Progress in treatments for pediatric rheumatic diseases, collaborative clinical trials, and personalized therapeutic approaches highlight the past year in rheumatology
Rheumatology Drug Updates
Information on new approvals and medication safety that rheumatologists need to know
EULAR 2013: New RA Recommendations Address Combination Therapy Concerns
Guidelines give greater nod to use of combination conventional disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis, leave monotherapy with methotrexate as acceptable first-line treatment
- « Previous Page
- 1
- …
- 111
- 112
- 113
- 114
- 115
- …
- 123
- Next Page »